Method for the treatment of chronic myelogenous leukemia
US4851219A · kind A · utility
3Cited by
1References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 18, 1986 |
| Grant date | Jul 25, 1989 |
| Priority date | — |
| Expiry date | Nov 18, 2006 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Gamma interferon is employed in the treatment of chronic myelogenous leukemia. Patients treated in the benign stage exhibit partial and, in some cases, complete responses to gamma interferon. Successful results have also been obtained with some patients in the blast stage of the disease as well as patients who had been found to be refractory to treatment with alpha interferon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.